A Phase III Clinical Trial Evaluating TheraSphere® in Patients with
Metastatic Colorectal Carcinoma of the Liver who have Failed First Line
Chemotherapy

Male or female, 18 years of age or older, and of any ethnic or racial group

ECOG PS 0-1 through screening to first treatment on study

If primary tumor has not been resected, it must be clinically stable

Colorectal cancer with unresectable metastatic disease to the liver with
disease progression in the liver with oxaliplatin or irinotecan based
1st line chemotherapy

Tumor replacement <50% of total liver volume

Must be eligible to receive second-line standard-of-care chemotherapy with either

an oxaliplatin-based chemotherapy regimen, or

an irinotecan-based chemotherapy regimen

Must have baseline efficacy images with measurable target tumors in the liver

Pancreas

ARMO Biosciences

AM0010-301

NCT02923921

A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared
with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic
Cancer that has Progressed During or Following a First-Line Gemcitabine
Containing Regimen

Presence of metastatic pancreatic adenocarcinoma

Documented tumor progression during or following a gemcitabine containing
regimen to treat metastatic disease as established by CT or MRI scan

Not received previous radiation therapy or investigational therapy for
advanced metastatic disease

Lymphoma/Leukemia

A multi-center, open-label, study to evaluate the safety and efficacy of
Ublituximab (TG-1101) in combination with TGR-1202 for patients previously
enrolled in protocol UTX-TGR-304

ECOG PS ≤ 2

Prior treatment in clinical trial UTX-TGR-304

NHL

TG Therapeutics
UTX-TGR-205

NCT02793583

UTX-TGR-205: A Phase 2b Randomized Study To Assess the Efficacy and Safety
of the Combination of Ublituximab + TGR-1202 with or without Bendamustine
and TGR-1202 alone in Patients with previously Treated Non-Hodgkin's Lymphoma.

Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of
other homologous recombination deficiency testosterone levels of ≤
50 ng/dL (1.73 nM)

Experienced disease progression after having received at least 1 but no
more than 2 prior next-generation androgen receptor-targeted therapies,
and 1 prior taxane-based chemotherapy, for castration resistant disease

A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type
for Eligibility Determination for Clinical Trials Evaluating the Safety
and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects
with Solid or Hematological Malignancies

Histologically- or cytologically-confirmed diagnosis of advanced solid
or hematologic malignancy or recurrent disease as described in the respective
Adaptimmune clinical treatment protocol (including, but not limited to
myeloma, melanoma, NSCLC, head & neck, gastric and bladder cancer)

Male or female ≥ 18 years of age

Life expectancy > 3 months

Ability to provide a blood sample

Ability to provide one of the following tumor tissue samples:

Formalin-fixed, paraffin-embedded (FFPE) tumor block or tissue sections
from a current lesion/the most current setting, or fresh biopsy is feasible OR

A FFPE archival primary tumor block or tissue sections

Stage IV / Metastatic NSCLC

ARMO Biosciences

AM0010-201 (CYPRESS-1)

NCT03382899

An Open-label Randomized Phase 2 Trial of AM0010 in Combination with Pembrolizumab
vs. Pembrolizumab Alone as First-line Therapy in Patients with Stage IV/Metastatic
Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (≥ 50%)